(Q37385293)

20 August 2017

12 references

25 June 2019

13 November 2019

20 November 2019

28 November 2019

11 December 2019

18 December 2019

19 December 2019

20 December 2019

23 September 2020

5 December 2020

21 December 2020

31 July 2022

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy (English)

1 reference

antineoplastic combined chemotherapy protocols

20 August 2017

0 references

1 reference

13 November 2019

1 reference

20 November 2019

1 reference

28 November 2019

1 reference

11 December 2019

1 reference

18 December 2019

1 reference

19 December 2019

1 reference

20 December 2019

1 reference

23 September 2020

1 reference

5 December 2020

1 reference

21 December 2020

B Rao

1

1 reference

20 August 2017

S Lain

series ordinal

2

1 reference

20 August 2017

A M Thompson

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

14 November 2013

1 reference

British Journal of Cancer

20 August 2017

10 December 2013

12 references

25 June 2019

13 November 2019

20 November 2019

28 November 2019

11 December 2019

18 December 2019

19 December 2019

20 December 2019

23 September 2020

5 December 2020

21 December 2020

31 July 2022

13 references

20 August 2017

25 June 2019

13 November 2019

20 November 2019

28 November 2019

11 December 2019

18 December 2019

19 December 2019

20 December 2019

23 September 2020

5 December 2020

21 December 2020

31 July 2022

109

1 reference

20 August 2017

12

1 reference

20 August 2017

2954-2958

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

20 August 2017

12 references

25 June 2019

13 November 2019

20 November 2019

28 November 2019

11 December 2019

18 December 2019

19 December 2019

20 December 2019

23 September 2020

5 December 2020

21 December 2020

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

31 July 2022

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Regulation of nucleolar signalling to p53 through NEDDylation of L11

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Exploiting cancer cell cycling for selective protection of normal cells.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

6 September 2017

Surfing the p53 network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Nucleolar Arf sequesters Mdm2 and activates p53

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Localization of gene for human p53 tumour antigen to band 17p13.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Cancer. p53, guardian of the genome

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

The interaction of actinomycin with DNA.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Stapled peptides with improved potency and specificity that activate p53.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859955

Clinical studies on actinomycin D with special reference to Wilms' tumor in children

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24231949

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24231949

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24231949

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2013.702

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24231949

1 reference